10-Q: QHSLab Inc. Reports Improved Revenue and Gross Profit in Q3 2024, But Going Concern Doubts Remain
Quarterly Report
QHSLab, Inc. saw increased revenue and gross profit in the third quarter of 2024, driven by growth in integrated service programs and allergy diagnostic kit sales, but faces ongoing concerns about its ability to continue as a going concern due to significant debt and defaults.
Summary
- QHSLab, Inc. reported a revenue of $544,285 for the three months ended September 30, 2024, compared to $336,407 for the same period in 2023.
- The company's revenue for the nine months ended September 30, 2024, was $1,505,945, up from $1,093,974 in the same period of 2023.
- Gross profit for the three months ended September 30, 2024, was $365,133, with a gross margin of 67.1%, compared to $189,510 and 56.3% in 2023.
- For the nine months ended September 30, 2024, gross profit was $945,736, with a gross margin of 62.8%, compared to $603,680 and 55.2% in 2023.
- The company experienced a net income of $49,765 for the three months ended September 30, 2024, compared to a net loss of $82,443 in 2023.
- For the nine months ended September 30, 2024, the company had a net income of $28,350, compared to a net loss of $381,725 in 2023.
- The company's operating expenses for the three months ended September 30, 2024, were $276,043, compared to $224,743 in 2023.
- Operating expenses for the nine months ended September 30, 2024, totaled $813,075, compared to $795,427 in 2023.
- The company's cash and cash equivalents increased to $95,945 as of September 30, 2024, from $51,582 at the end of 2023.
- QHSLab has significant debt, including convertible notes payable of $1,223,500 and loans payable of $482,668, and is in default on several of these obligations.
- The company has an accumulated deficit of $4,014,143 as of September 30, 2024.
- The company's management has expressed substantial doubt about its ability to continue as a going concern.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While there are positive signs of revenue growth and improved profitability, the significant debt, defaults, and going concern issues raise serious concerns about the company's long-term viability. The sentiment is cautiously optimistic but with a strong dose of realism about the challenges ahead.
Positives
- The company experienced a substantial increase in revenue, particularly from its Integrated Service Program.
- Gross profit margins improved significantly, indicating better cost management and pricing strategies.
- QHSLab achieved net income for both the three and nine-month periods ending September 30, 2024, a turnaround from previous losses.
- The company's cash position improved, and it generated positive cash flow from operations.
- The company has expanded its offerings to include clinical study services.
Negatives
- QHSLab has a significant amount of debt, including convertible notes and loans payable.
- The company is in default on several of its debt obligations.
- Management has expressed substantial doubt about the company's ability to continue as a going concern.
- The company has an accumulated deficit of over $4 million.
- The company's disclosure controls and procedures were deemed ineffective due to a lack of adequate personnel.
Risks
- The company's ability to continue as a going concern is uncertain due to its high debt levels and defaults.
- There is a risk that lenders may exercise their rights under default provisions, potentially leading to foreclosure on assets.
- The company may face challenges in raising additional capital on favorable terms.
- The company's reliance on a small number of customers could pose a risk if those relationships are disrupted.
- The company's internal controls are not effective, which could lead to errors in financial reporting.
Future Outlook
The company plans to increase revenues by expanding its physician network, introducing new products, and charging subscription fees for its QHSLab software. However, the company's ability to operate profitably is dependent on its ability to generate revenues and secure additional financing.
Management Comments
- Management believes the information provided is relevant to an assessment and understanding of the company's results of operations and financial condition.
- Management acknowledges that the company is highly leveraged and has only recently begun to generate cash from operations.
- Management has expressed substantial doubt about the company's ability to continue as a going concern.
- Management has identified corrective actions for the weakness in internal controls and will periodically reevaluate the ability to add personnel and implement improved review procedures.
Industry Context
The company operates in the value-based healthcare, digital therapeutics, and remote patient monitoring sectors, which are experiencing growth due to increasing recognition of the benefits of these technologies. The company's focus on enabling primary care physicians to manage chronic diseases aligns with the trend towards more frequent and shorter patient encounters, often without direct physician participation.
Comparison to Industry Standards
- QHSLab's revenue growth in the third quarter of 2024 is a positive sign, but its financial position is weaker than many established companies in the medical device and SaaS sectors.
- Companies like Teladoc Health and Livongo (now part of Teladoc) have demonstrated the potential for growth in the telehealth and remote patient monitoring space, but they also have significantly more capital and established customer bases.
- QHSLab's gross margin of 67.1% in the third quarter is competitive with some SaaS companies, but its overall financial health is hampered by its debt and going concern issues.
- Compared to companies like Dexcom or Insulet in the medical device space, QHSLab is much smaller and has a less established product portfolio and market presence.
- The company's reliance on convertible debt and its defaults are not typical of well-established companies in the healthcare technology sector.
Related Party Transactions
- Amounts due to related parties consist of cash advances received from the principal shareholder, bear no interest, and are due on demand.
- The company has convertible notes payable to a shareholder.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and potential dilution from future capital raises.
- Employees may be concerned about job security given the company's going concern issues.
- Customers (physicians) may be impacted if the company is unable to continue providing its products and services.
- Creditors face the risk of not being repaid due to the company's defaults and financial difficulties.
Next Steps
- The company plans to increase revenues by expanding its physician network and introducing new products.
- The company will continue to upgrade its QHSLab software.
- The company will seek to obtain necessary equity or debt financing.
- The company will attempt to convince the holders of its notes to forbear from exercising any rights they might have as a result of its defaults.
Key Dates
| Date | Description |
|---|---|
| 2021-05-07 | Effective date of a Convertible Promissory Note issued to a shareholder. |
| 2021-06-21 | Date of Series A2 Preferred Stock issuance. |
| 2021-06-23 | Date of purchase agreement to acquire assets from MedScience Research Group, Inc. |
| 2021-08-10 | Effective date of a Securities Purchase Agreement with Mercer Street Global Opportunity Fund, LLC. |
| 2021-11-11 | Mercer Fund converted $50,000 of the principal amount of the $806,000 Note. |
| 2021-12-29 | Date of Series A2 Preferred Stock issuance. |
| 2022-07-19 | Effective date of a Securities Purchase Agreement with Mercer Fund for the $440,000 Note. |
| 2022-07-27 | Mercer Fund converted $50,000 of the principal amount of the $806,000 Note. |
| 2023-10-05 | Company agreed to reduce the conversion price with respect to $10,500 of the amounts payable pursuant to the $806,000 Note. |
| 2024-02-19 | Company received a notice of forbearance from Mercer Fund and MedScience. |
| 2024-03-04 | Company agreed to reduce the conversion price with respect to $12,000 of the amounts payable pursuant to the $806,000 Note. |
| 2024-08-12 | Company entered into a fixed-fee short-term loan with its merchant bank. |
| 2024-09-30 | End of the quarterly period covered by the report. |
| 2024-10-18 | Company entered into a Consulting Agreement with Juan D. Oms, MD, FAPA. |
| 2024-11-13 | Date of the report. |
Keywords
QHSLab, healthcare, medical device, SaaS, allergy diagnostics, immunotherapy, integrated service program, clinical study, revenue, gross profit, debt, going concern, financial results
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.